Skip to main content

Xortx Therapeutics Inc(XRTX-X)
TSX Venture

Today's Change
Delayed Last Update

Xortx Therapeutics Inc

3710 - 33rd Street NW
Calgary AB T2L 2M1 CAN
P: 403-455-7727
F: 403-260-3501
https://www.xortx.com

Sectors & Indices

Sector
Industry
Employees

Profile

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Key Executives

NameTitle
Allen Warren DavidoffCEO/Director/President
Michael BumbyCFO
Stephen HaworthChief Medical Officer
Stacy EvansOther Executive Officer

More from The Globe

Analysts’ forecast returns, recommendations and yields for all stocks in the S&P/TSX SmallCap Index
The S&P TSX composite index screen at the TMX Market Centre in Toronto is photographed on Friday, November 11, 2022.
Small caps to watch: Aecon, Maple Leaf Foods, Tecsys and more
Packages of Maple Leaf Foods chicken breasts are shown on a shelf at a grocery store in Oakville, Ont., Friday, Jan.6, 2023.
Thursday’s analyst upgrades and downgrades
A pumpjack operates at the Vermilion Energy site in Trigueres, France, June 14, 2024.
Wednesday’s analyst upgrades and downgrades
A Pet Valu store is pictured in Ottawa, Tuesday, Sept. 13, 2022.
number cruncher
Seven Canadian oil producers set to benefit from rising prices
For Number Cruncher column in Globe Investor/ROB only.
Bullish on Mullen Group Ltd.
Monica Rizk
Top non-resource stocks on the TSX with strong insider signals
Ted Dixon
Berkshire Hathaway shares have largest slide since Buffett’s resignation
FILE PHOTO: A screen displays the trading information for Berkshire Hathaway inc. as traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., October 22, 2025. REUTERS/Brendan McDermid/File Photo

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Financial data provided by Zacks Investment Research.